Is ENTA or ENVB more undervalued in 2026?

CirclFi compares Enanta Pharmaceuticals, Inc. (ENTA) and Enveric Biosciences, Inc. (ENVB) using 13 institutional-grade valuation models. ENTA has a Quality of Company score of 5.1/10 while ENVB scores 3.8/10.

Which is a better buy — ENTA or ENVB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ENTA and ENVB valuations compare?

ENTA at $13.23 and ENVB at $2.32 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ENTA vs ENVB Valuation Comparison 2026 — Intrinsic Value Analysis

ENTA

Biotechnology

Enanta Pharmaceuticals, Inc.

Quality

5.1

out of 10

Value Trap

LOW

Price

$13.23

Last close

Models

10/13

Active

ENVB

Biotechnology

Enveric Biosciences, Inc.

Quality

3.8

out of 10

Value Trap

LOW

Price

$2.32

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	ENTA Fair Value	ENTA Upside	ENVB Fair Value	ENVB Upside
Bayesian DCF	Intrinsic	$2.32	-82.5%	$1.35	-41.8%
Earnings Power Value	Intrinsic	—	—	$2.37	-40.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.03	-92.5%	$2.37	+2.0%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ENTA vs ENVB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ENTA vs ENVB — Which Stock Is More Undervalued?

ENTA scores higher with a 5.1/10 quality rating vs ENVB's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Enanta Pharmaceuticals, Inc. (ENTA) and Enveric Biosciences, Inc. (ENVB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ENTA currently trades at $13.23 with a QOC of 5.1/10, while ENVB trades at $2.32 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).